Company | Cap $ | P/E | P/B | P/S | ROE | ROA | ROS | L/A | P/FCF | PR | Period |
---|---|---|---|---|---|---|---|---|---|---|---|
Fulgent Genetics | 720 | 2021 | |||||||||
Galera Therapeutics | 1 | 2021 | |||||||||
Gamida Cell | 23 | 2021 | |||||||||
Genmab | 14,947 | 2024q1 | |||||||||
GeoVax Labs | 158 | 2021 | |||||||||
Gilead Sciences | 120,067 | 2024q2 | |||||||||
Glaukos | 3,388 | 2023q3 | |||||||||
Globus Medical | 5,058 | 2023q2 | |||||||||
Gossamer Bio | 130 | 2023q1 | |||||||||
GSK | 106,510 | 2022q1 | |||||||||
Guardant Health | 2,631 | 2023 | |||||||||
Guardion Health Sciences | 491 | 2021 | |||||||||
Haemonetics | 3,912 | 2025q1 | |||||||||
Halozyme Therapeutics | 5,427 | 2022 | |||||||||
Hansoh Pharmaceutical Gro... | 9,732 | 2023 | |||||||||
HCA Healthcare | 61,594 | 2023q3 | |||||||||
Health Catalyst | 483 | 2023 | |||||||||
HealthEquity | 6,856 | 2023 | |||||||||
Henry Schein | 9,248 | 2023q2 | |||||||||
Heron Therapeutics | 266 | 2023q3 |